The sale of FibroGen China to AstraZeneca PLC simplifies the company's operations and cleans up its balance sheet, CEO Thane ...

China’s share of the global drug development pipeline grew from 3% in 2013 to 28% in 2023, positioning China as the second-largest region for clinical trials after the United States. Additionally, the ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

A rare Beijing powwow brought together CEOs and entrepreneurs with growing global influence.

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to ...

Signet Therapeutics, a clinical-stage biotech company leveraging organoid- and AI-driven cancer drug discovery, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Clearside Biomedical (CLSD) reported that Arctic Vision’s New Drug Application or NDA for arcatus for the treatment of uveitic macular edema ...